Miconazole (buccal)

Miconazole (buccal)
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Kiran Singh, M.D. [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Miconazole (buccal) is an antifungal that is FDA approved for the treatment of oropharyngeal candidiasis in adults. Common adverse reactions include diarrhea, headache, nausea, dysgeusia, upper abdominal pain, and vomiting.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Indications

• ORAVIG is indicated for the local treatment of oropharyngeal candidiasis (OPC) in adults.

Dosing

• The recommended dosing schedule for ORAVIG is the application of one 50 mg buccal tablet to the upper gum region (canine fossa) once daily for 14 consecutive days.

DOSAGE FORMS AND STRENGTHS

• ORAVIG is a buccal tablet containing 50 mg of miconazole. ORAVIG tablets are round, off-white tablets, with a rounded side and a flat side. The tablets are marked with an “L” on the flat side.

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Miconazole (buccal) in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Miconazole (buccal) in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding FDA-Labeled Use of Miconazole (buccal) in pediatric patients.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Miconazole (buccal) in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Miconazole (buccal) in pediatric patients.

Contraindications

• ORAVIG is contraindicated in patients with known hypersensitivity (e.g., anaphylaxis) to miconazole, milk protein concentrate, or any other component of the product.

Warnings

Hypersensitivity

• Allergic reactions, including anaphylactic reactions and hypersensitivity, have been reported with the administration of miconazole products, including ORAVIG. Discontinue ORAVIG immediately at the first sign of hypersensitivity.

• There is no information regarding cross-hypersensitivity between miconazole and other azole antifungal agents. Monitor patients with a history of hypersensitivity to azoles.

Adverse Reactions

Clinical Trials Experience

• The following serious adverse drug reactions are discussed in detail in other sections of labeling:

• Hypersensitivity reactions

Clinical Trial Experience

• Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

• The overall safety of ORAVIG was assessed in 480 adult subjects: 315 HIV-infected subjects, 147 subjects with head and neck cancer, and 18 healthy subjects.

HIV Infected Patients

• Two trials were conducted in immunocompromised HIV infected patients: one randomized, double-blind, double-dummy, active-controlled design (N = 290 ORAVIG, 287 control) and one non-comparative trial (N = 25).

• In the randomized, double blind trial (Study 1), 290 HIV infected subjects used ORAVIG once daily for 14 days, and 287 subjects used 10 mg clotrimazole troches five times daily for 14 days. Adverse reactions occurring in ≥ 2% of patients in either treatment are presented in Table 1.

This image is provided by the National Library of Medicine.

• Overall local adverse reactions, including oral discomfort, oral burning, oral pain, gingival pain, gingival swelling, gingival pruritis, tongue ulceration, mouth ulceration, glossodynia, dry mouth, application site pain or discomfort, toothache, loss of taste, and altered taste, were reported by 35 (12.1%) patients who received miconazole buccal tablet compared to 27 (9.4%) patients who received clotrimazole troches.

Head and Neck Cancer Patients

• In the randomized, open-label comparative trial of oropharyngeal candidiasis in patients with head and neck cancer who had received radiation therapy (Study 2), 147 patients used ORAVIG once daily for 14 days and 147 patients used 125 mg of miconazole oral gel four times daily for 14 days. Adverse reactions occurring in ≥2% of patients in either arm are listed in Table 2.

[[File:Miconazole buccal table2.png[|thumb|none|600px|This image is provided by the National Library of Medicine.]]

Overall local adverse reactions, including oral discomfort, oral pain, dry mouth, glossodynia, loss of taste, altered taste, tongue ulceration, mouth ulceration, tooth disorder, and application site discomfort or pain, were experienced by 14 (9.5%) patients who used ORAVIG compared to 16 (10.9%) patients who used miconazole gel.

This image is provided by the National Library of Medicine.

Overall ORAVIG Safety Experience In Patients and Healthy Subjects

• Adverse reactions reported in the overall safety database of 480 subjects who received miconazole buccal tablet is listed in Table 3.

This image is provided by the National Library of Medicine.

• Discontinuation of ORAVIG due to adverse drug reactions occurred in 0.6% overall.

Postmarketing Experience

There is limited information regarding Postmarketing Experience of Miconazole (buccal) in the drug label.

Drug Interactions

Warfarin

• Concomitant administration of miconazole and warfarin has resulted in enhancement of anticoagulant effect. Cases of bleeding and bruising following the concomitant use of warfarin and topical, intravaginal, or oral miconazole were reported. Closely monitor prothrombin time, International Normalized Ratio (INR), or other suitable anticoagulation tests if ORAVIG is administered concomitantly with warfarin. Also monitor for evidence of bleeding.

Drugs Metabolized Through CYP2C9 and 3A4

• No formal drug interaction studies have been performed with ORAVIG. Miconazole is a known inhibitor of CYP2C9 and CYP3A4. Although the systemic absorption of miconazole following ORAVIG administration is minimal and plasma concentrations of miconazole are substantially lower than when given intravenously, the potential for interaction with drugs metabolized through CYP2C9 and CYP3A4 such as oral hypoglycemics, phenytoin, or ergot alkaloids cannot be ruled out.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): There is no FDA guidance on usage of Miconazole (buccal) in women who are pregnant.
Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Miconazole (buccal) in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Miconazole (buccal) during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Miconazole (buccal) with respect to nursing mothers.

Pediatric Use

There is no FDA guidance on the use of Miconazole (buccal) with respect to pediatric patients.

Geriatic Use

There is no FDA guidance on the use of Miconazole (buccal) with respect to geriatric patients.

Gender

There is no FDA guidance on the use of Miconazole (buccal) with respect to specific gender populations.

Race

There is no FDA guidance on the use of Miconazole (buccal) with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Miconazole (buccal) in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Miconazole (buccal) in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Miconazole (buccal) in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Miconazole (buccal) in patients who are immunocompromised.

Administration and Monitoring

Administration

• Oral

Monitoring

There is limited information regarding Monitoring of Miconazole (buccal) in the drug label.

IV Compatibility

There is limited information regarding IV Compatibility of Miconazole (buccal) in the drug label.

Overdosage

• Overdose with miconazole in humans has not been reported in the literature.

• Miconazole absorption and systemic exposure following application of ORAVIG are minimal.

• Symptomatic and supportive care is the basis for management.

Pharmacology

There is limited information regarding Miconazole (buccal) Pharmacology in the drug label.

Mechanism of Action

There is limited information regarding Miconazole (buccal) Mechanism of Action in the drug label.

Structure

There is limited information regarding Miconazole (buccal) Structure in the drug label.

Pharmacodynamics

There is limited information regarding Pharmacodynamics of Miconazole (buccal) in the drug label.

Pharmacokinetics

There is limited information regarding Pharmacokinetics of Miconazole (buccal) in the drug label.

Nonclinical Toxicology

There is limited information regarding Nonclinical Toxicology of Miconazole (buccal) in the drug label.

Clinical Studies

There is limited information regarding Clinical Studies of Miconazole (buccal) in the drug label.

How Supplied

Storage

There is limited information regarding Miconazole (buccal) Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Miconazole (buccal) |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Miconazole (buccal) |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Patient Counseling Information of Miconazole (buccal) in the drug label.

Precautions with Alcohol

• Alcohol-Miconazole (buccal) interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

• ORAVIG®

Look-Alike Drug Names

• A® — B®

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.

{{#subobject:

 |Page Name=Miconazole (buccal)
 |Pill Name=No image.jpg
 |Drug Name=
 |Pill Ingred=|+sep=;
 |Pill Imprint=
 |Pill Dosage={{{dosageValue}}} {{{dosageUnit}}}
 |Pill Color=|+sep=;
 |Pill Shape=
 |Pill Size (mm)=
 |Pill Scoring=
 |Pill Image=
 |Drug Author=
 |NDC=

}}

{{#subobject:

 |Label Page=Miconazole (buccal)
 |Label Name=Miconazole (buccal)11.png

}}

{{#subobject:

 |Label Page=Miconazole (buccal)
 |Label Name=Miconazole (buccal)11.png

}}